

CURRICULUM VITAE OF:

WILLIAM B. WEBSTER, Pharm. D., FCCP, BCPS

Home Address	9525 Blind Pass Rd. Courageous # 1001 St. Pete Beach, Florida 33706
Home Telephone	(727) 363-0072
Education	Doctor of Pharmacy - 1984 College of Pharmacy, University of Florida Gainesville, Florida B.S. Pharmacy College of Pharmacy, University of South Carolina Columbia, South Carolina
Professional Experience Present	Medical Rounds, Inc Consultant Consultant Bay Pines VA Health System Infectious Diseases Service St Petersburg, Florida
2005 to Oct. 2008	Schering-Plough Corporation 2000 Galloping Hill Road Kenilworth, New Jersey 07033-0530 Regional Medical Science Liaison, Infectious Diseases
2004 to 2005	Regional Medical Science Liaison, Respiratory/Allergy Global Medical Affairs Territory: Southeast US
2002 to 2004	Aventis 300 Somerset Corporate Boulevard Bridgewater, NJ 08807-0977 Medical Scientific Manager January 4, 2002 to October 29, 2004 Medical Affairs: Infectious Diseases/Respiratory Territory: Central and North Florida

2000 to 2002	Director, Clinical Research Research & Development Bay Pines VA Medical Center, Bay Pines, Florida
1984 to 2000	Clinical Education/Programs Manager Department of Pharmacy Services Bay Pines VA Medical Center, Bay Pines, Florida
1994 to 1999	Residency Program Director Department of Pharmacy Services Bay Pines VA Medical Center, Bay Pines, Florida
1992 to 2002	Director, Biotechnology Research Group Bay Pines VA Medical Center, Bay Pines, Florida
1984 to 2000	Clinical Pharmacist Specialist, Critical Care Pharmacotherapy Bay Pines VA Medical Center, Bay Pines, Florida
1984 to 2000	Clinical Coordinator Department of Pharmacy Services Bay Pines VA Medical Center, Bay Pines, Florida
1981	Director of Pharmacy, Student Health Services East Carolina University
1979 to 1981	Assistant Director of Pharmacology and Pharmacy Services East Carolina University School of Medicine Department of Family Practice, Greenville, North Carolina
1968 to 1978	Private Practice, Fairmont, North Carolina Owner, Webster's Pharmacy, Inc.
1966 to 1967	Internship, Greenville South Carolina
Academic Appointments	1997 to present <i>Clinical Professor of Pharmacy</i> NOVA Southeastern University, Ft. Lauderdale
2000 to present	Adjunct Professor Mercer University, Southern College of Pharmacy Atlanta, Georgia
1994 to 2000	Clinical Faculty Mercer University, Southern College of Pharmacy Atlanta, Georgia

1989 to 1997	Clinical Associate Professor of Pharmacy Southeastern University, Miami, Florida
1989 to present	Clinical Associate Professor of Pharmacy University of Florida, Gainesville, Florida
1985 to 1989	Clinical Assistant Professor of Pharmacy University of Florida, Gainesville, Florida
2000 to 2002	Courtesy Adjunct Professor, Department of Natural Science St. Petersburg Junior College, St Petersburg, Florida
1979 to 1981	Lecturer, East Carolina University School of Medicine
Board Certification	August 17, 1991 Pharmacotherapy Board, BPS # 291140 Board of Pharmaceutical Specialties American Pharmaceutical Association October 3, 1998 Recertified by examination October 1, 2005 Recertified by examination
Additional Training	May 1990 Oak Ridge Associated Universities Radiopharmaceutical Internal Dose Calculation Techniques Course Oak Ridge Tennessee
Awards and Honors	2005 Elected Fellow American College of Clinical Pharmacy 1992 Scientific Poster Award: Pharmacy World Congress International Pharmaceutical Federation 52nd International Congress of Pharmaceutical Sciences of FIP 1990-1991 Syntex Award: Preceptor of the year Southeastern University, College of Pharmacy, Miami Elected 1976 Fellowship: American College of Apothecaries

	Elected 1976 Membership: North Carolina Academy of Pharmacy
Other Awards	2007 Leadership Recognition Award Schering-Plough, Global Medical Affairs 2003 Regional Team Player Award Aventis, Medical Scientific Team
Reviewer/Item Writer	2003 to present <i>Journal of Pharmaceutical Sciences</i> July 1997 UHC Drug Monographs Series December 1996 to present <i>Annals of Pharmacotherapy</i> August 1996 to present <i>Pharmacotherapy</i> December 1991, April 1999 Board of Pharmaceutical Specialties Pharmacotherapy Examination
Principal Post-Doctoral Preceptor	July 1991 Post-Doctoral Fellowship established <i>Biotechnology: Antibody Immunoconjugates and Immunotherapeutics</i> , Fellows: 1991-1992 Jamini Patel, Ph.D. 1996-1997 Andrew Nasarri, M.D. Candidate
	July 1999 General Post-Doctoral Research Fellowship Fellow: 1999-2000 Andrew Nasarri, M.D.
Graduate Student Preceptor	July 1993 Mathematics/Biostatistics Fellow: Marnie S. Hatton, Department of Mathematics

University of South Florida, Tampa Florida

Professional Societies

Society of Infectious Disease Pharmacist
Elected to membership 2007
American College of Clinical Pharmacy
Research Affairs Committee 1998-1999
Research Affairs Committee 1999-2000
Education Affairs Committee 2003-04
Education Affairs Committee 2004-05
Credentials, FCCP Committee 2006-07
Vice Chairman 2007-2008
Chairman 2008
Florida Infectious Diseases Society (FIDS)
Full Member 2005 to present

Licensure

1982 Florida No. PS0019948
1967 South Carolina No. 3462 (inactive status)

Research

1995 Supporting authority for hearing before FDA/CBER
^{99m}Tc-Labelled Anti-Granulocyte Antibody Fab, Sulesomab
(LeuScan™)

1986 to 2002 Pharmacokinetics and Tissue Distribution of
Radiolabeled Monoclonal Antibodies and other
Radioimmunoassays and Radioimmunotherapeutics
In association with: Steven J. Harwood, M.D., Ph.D.,
Robert G. Carroll, M.D.

1982 to 1984 Stereospecific Binding of Propranolol to Serum
Proteins
In association with: John A. Pieper, Pharm.D.

1980 to 1982 Determination of Pancreatic Alpha Subtype
Receptors by Radioligand Binding Technique
In association with: Mona M. McConnaughey, Ph.D.

Publications

Webster WB, McConnaughey MM. Clonidine and Glucose Intolerance. *Drug Intelligence and Clinical Pharmacy* 1982; 16:325-328.

Kaplan RF, Feinglass NC, **Webster WB**, Mudra S. Phenezine Overdose Treated with Dantrolene Sodium - *JAMA* 1986; 255: 642-644.

Harwood SJ, **Webster W**, et al. Comparison of Human Biodistribution and Differences Between ¹³¹Iodine and ¹¹¹Indium Labeled B72.3 Monoclonal Antibody. *Cancer Research (Suppl.)*, 1990; 50: 932s-936s.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA. Pharmacokinetics of ¹¹¹In-Labeled B72.3 Monoclonal Antibody in Colorectal Cancer Patients. *The Journal of Nuclear Medicine* 1992; 33: 498-504.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA. A reply to: Mean Time Parameters Reveal Differences in the Pharmacokinetics of Indium-111 and Iodine-131-labeled B72.3 Monoclonal Antibody. *The Journal of Nuclear Medicine* 1992; 33: 2248-2249.

Webster WB, Laven DL. Pharmacokinetics and Biologic Distribution Studies of Indium-111-Labeled Monoclonal Antibodies. *New Perspectives in Cancer Diagnosis and Management* 1993; 1: 12-19.

Harwood SJ, Camblin JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, Patel JU, **Webster WB** and Carroll RG. Use of Technetium Anti-Granulocyte Monoclonal Antibody Fab' Fragments for the Detection of Osteomyelitis. *Cell Biophysics* 1994; 24/25: 99-107.

Laucka PV, **Webster WB**, Kuch J. Pharmacist Review to Simplify Medication Regimens in A VAMC Primary Care Clinic. *Journal of Pharmacy Technology* 1996; 12: 62-6.

Hakki S, Harwood SJ, Morrissey MA, Camblin JG, Laven DL, **Webster WB**. Comparative Study of Monoclonal Antibody Scan in Diagnosing Orthopaedic Infection. *Clinical Orthopaedics and Related Research* 1997; 335: 275-285.

Banoob DW, McCloskey WW, **Webster W**. Risk of gastric injury with enteric- versus nonenteric-coated aspirin. *Ann Pharmacother.* 2002 Jan;36(1):163-6

Harwood SJ, Gibbons LK, Goldner PJ, **Webster WB**, Carroll RG. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure. *Cancer.* 2002 Feb 15;94(4 Suppl):1358-62.

Book Chapter

Harwood SJ, **Webster WB**, et al. Phase I Clinical Trial of ¹¹¹Indium 7E11-C5.3 (CYT-356) for the Detection of Prostate Carcinoma. in

Monoclonal Antibodies 2: Applications in Clinical Oncology. Epenetos E, Editor. Chapman & Hall Medical, London. 1993: 305-320.

Contributing Reviewer

Peters DH, Fitton A. (**Webster WB** Reviewer) Satumomab Pentetide: A preliminary Review of Its Use in the Diagnosis of Colorectal and Ovarian Cancer. *Clinical Immunotherapy* 1995; 3(5):395-408.

Grant KL, Abarca J. (**Webster WB** Contributing Reviewer) UHC Drug Monograph: MIBEFRADIL. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. December 1997.

Leslie D. (**Webster WB** Contributing Reviewer)UHC Drug Monograph: CARVEDILOL. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. December 1997.

Gardner SF (**Webster WB** Contributing Reviewer)UHC Drug Monograph: ANGIOTENSIN II RECEPTOR ANTAGONIST. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. August 1998.

Tortorice P (**Webster WB** Contributing Reviewer) UHC Drug Monographs: RITUXIMAB. University Health System Consortium Services Corporation, Oak Brook, IL 60523-1890. December 1999.

Invited Oral Presentations of Research

Pharmacokinetic and Bioequivalence Studies of Targeted Delivery Systems: Evaluation of Radio-Immuno-Pharmaceuticals as Drugs. Given at: *8th Annual DLA Biotechnology Workshop, BIOTECHNOLOGY: Global Perspectives, Dana Point, California, March 6-7, 2000.*

Pharmacokinetic Studies of Radiolabeled Monoclonal Antibodies: Non-Compartmental and Mean-Time Analysis. Given at: *Midyear Clinical Meeting, American Society of Hospital Pharmacist, New Orleans, December 8-12, 1991.*

Podium Presentations of Original Research

Diagnostic Scanning in Orthopaedic Infections: A Comparative Study of Tc-99m MAb Scans with In-111 WBC and Tc-99m MDP Bone Scans. Hakki, S, Harwood, SJ, Camblin, JG, Morrissey, MA, Laven, D, and **Webster, WB**. Given at: *Annual Meeting 1996, American Academy of Orthopaedic Surgeons, Atlanta, Georgia, February 22 to 26 1996.*

Effect of Human Antimouse Antibody, HAMA, on Plasma Mean-time Pharmacokinetics and Distribution of ^{111}In -radiolabeled B72.3 Monoclonal Antibody in Colorectal Cancer Patients. **Webster, WB**. Given at: *The Seventh International Symposium On Radiopharmacology, Boston, Massachusetts, June 3-6, 1991.*

Patient Interpretation of the Chemstrip bG Method of Home Glucose Monitoring. **Webster, WB**. Given at: *Fourteenth Annual Southeastern Conference for Post-Graduate Pharmacy Education and Training, Athens Georgia, March 12, 1983.*

Published Abstracts

Webster WB, Pieper JA. Stereospecific Protein Binding of Propranolol. Abstract in: *Drug Intelligence and Clinical Pharmacy 1985; 19:463.*

Harwood SJ, **Webster WB**, et al. Pharmacokinetics and Tissue Distribution of ^{111}In -ZCE-025 Anti-CEA Monoclonal Fab' Fragments. Abstract in: *J. Nuclear Med. 1987; 20: 1791.*

Harwood SJ, McDonald LM, Elkin MF, Laven DL, Sinni BJ, **Webster WB**, Carroll RG. Biodistribution Differences in Nude Mice and Man. Abstract in: *J. Nuclear Med. 1988;29: 2029.*

Harwood SJ, Carroll RG, DeRuzzo ST, **Webster WB**, et al. Biodistribution of ^{111}In -ZCE-025 Anti-CEA Monoclonal Fab Fragments. Abstract in: *J. Nuclear Med. 1988; 29: 896.*

Webster WB, et al. Analysis of Plasma and Tissue Distribution Pharmacokinetics for ^{111}In -B72.3 Monoclonal Antibody in Colorectal Cancer Patients. Abstract in: *Antibody Immunoconjugates, and Radiopharmaceuticals. 1988; 3: 78.*

Webster WB, et al. Development of Mean Transit and Residence Time Analysis of Radiolabeled Murine Monoclonal Antibody Distribution and Clearance. Abstract in: *Pharmacotherapy. 1988;10: 54.*

Webster WB, et al. Plasma and Tissue Distribution Pharmacokinetics of ^{111}In Murine Anti-CEA Monoclonal Antibody in Colorectal Cancer Patients; Abstract in: *European Journal of Nuclear Medicine. 1988; 10: 574.*

Webster WB, et al. Pharmacokinetics of ^{111}In -ZCE025 Mab in Colorectal Cancer Patients: Effect of CEA on Mean-Time Parameters; Abstract in: *Antibody Immunoconjugates and Radiopharmaceuticals. 1992; 5: 141.*

Webster WB, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Determining *In Vivo* ¹¹¹In-B72.3 Specific Binding by Pharmacokinetic Analysis of Plasma Clearance; Abstract in: *Antibody Immunoconjugates and Radiopharmaceuticals*. 1992; 5(3): 356.

Webster WB, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Plasma Pharmacokinetics of ¹¹¹In-CYT-356 Prostate Antibody; Abstract in: *Antibody Immunoconjugates and Radiopharmaceuticals*. 1992; 5(3): 356.

Harwood SJ, Camblin JG, Morrissey MA, Laven DL, Zangara LM, Patel JU, Carroll RG, **Webster WB**. Comparison of TC-99m IMMURAID™-MN3 Anti-granulocyte MAb Fab' Fragments and In-111 WBC's for detection of Osteomyelitis; Abstract in: *J. Nucl. Med*. 1994; 89: 35P.

Evans Branch, III, Lynne C. Krop, J. Mark Trotter, and **William B. Webster**. Cephalosporin Usage and the Emergence of Enterococcal Isolates; Abstract in: *International Pharmaceutical Abstracts*. 1995; 32(21): 2329.

Webster WB, Harwood SH, Carroll RG, Morrissey M, Hakki S. Comparative Pharmacokinetics, Dosimetry, and *In-Vivo* stability of two formulations of ^{99m}Tc-Labeled Anti-granulocyte Antibody Fab' Fragment (IMMU-MN3, Leukoscan™); Abstract in: *Pharmacotherapy*. 1996; 16(1): 131-2.

Hakki S, Harwood SJ, Morrissey MA, Camblin JG, Laven DL, **Webster WB**. Comparative Study of Monoclonal Antibody Scan in Diagnosing Orthopaedic Infections: A Comparison of Tc-99m Monoclonal Antibody Scans, with Indium-111 White Blood Cell and Technetium-99m Medronate Diphosphate Bone Scans *Orthopaedic Transactions* 1996;20.

Hakki S, Harwood SJ, Morrissey MA, Camblin JG, Laven DL, **Webster WB**. Comparative Study of Monoclonal Antibody Scan in Diagnosing Orthopaedic Infection. *Clinical Orthopaedics and Related Research* 1996; 335: 275-285. Abstracted in *Yearbook of Nuclear Medicine*, 1998.

William B. Webster, Tina Vo., Andrew F. Nasser, Steven J. Harwood, Sam Hakki, Robert G. Carroll, Michele Morrissey, John Camblin, Tatjana Webster. An Open Label Study Evaluating the Pharmacokinetics of ^{99m}Technetium P280 (Diagnostic Agent) in Patients at Risk for Venous Thrombosis; Abstract in: *Pharmacotherapy*. 1999;19(10): 1216-7.

Webster WB, Harwood SJ, Carroll, RW, Gibbons L, Sochet A, Tantranond P, Morrissey M, Goldner P, Deruzzo S, Fahrendorf T. Patient Specific Radioimmunotherapy of Non-Hodgkin's Lymphoma with Iodine-131-Anti-B1 Antibody (iodine I 131 Tositumomab): Pharmacokinetic Dosing. Abstract in: *Pharmacotherapy*. 2000;20(3): 352-3.

Webster WB, Harwood SJ, Carroll R, Hakki S, Camblin J, Gibbons L, Morrissey M, Goldner, P, Deruzzo S, Fahrendorf T. Bioequivalence Pharmacokinetic Studies of Two Formulations of ^{99m}Tc-Labelled Anti-Granulocyte Antibody Fab' Fragment, Sulesomab (LeuScan™): Evaluation of a Radiopharmaceutical As a Drug – What Difference Is Important. Abstract in: *Cancer Biotherapy & Radiopharmaceuticals*. 2000;15(4): 411.

Webster WB, Harwood SJ, Carroll R, Gibbons L, Sochet A, Tantranond P, Morrissey M. Outpatient Therapy of Non-Hodgkin's Lymphoma with Iodine-131-Anti-B1 Antibody: Innovative Administration Techniques for Minimizing Radiation Exposure. Abstract in: *Cancer Biotherapy & Radiopharmaceuticals*. 2000;15(4): 414.

Poster Presentations

Bioequivalence Pharmacokinetic Studies of Two Formulations of ^{99m}Tc-Labelled Anti-Granulocyte Antibody Fab' Fragment, Sulesomab (LeuScan™): Evaluation of a Radiopharmaceutical As a Drug – What Difference Is Important. **Webster WB**, Harwood SJ, Carroll R, Hakki S, Camblin J, Gibbons L, Morrissey M, Goldner, P, Deruzzo S, Fahrendorf T. Presented at: *Eighth Conference on Radioimmunodection and Radioimmunotherapy of Cancer, Princeton, NJ, October 12-14, 2000*.

Outpatient Therapy of Non-Hodgkin's Lymphoma with Iodine-131-Anti-B1 Antibody: Innovative Administration Techniques for Minimizing Radiation Exposure. **Webster WB**, Harwood SJ, Carroll R, Gibbons L, Sochet A, Tantranond P, Morrissey M. Presented at: *Eighth Conference on Radioimmunodection and Radioimmunotherapy of Cancer, Princeton, NJ, October 12-14, 2000*.

Patient Specific Radioimmunotherapy of Non-Hodgkin's Lymphoma with Iodine-131-Anti-B1 Antibody (iodine I 131 Tositumomab): Pharmacokinetic Dosing. **Webster WB**, Harwood SJ, Carroll, RW, Gibbons L, Sochet A, Tantranond P, Morrissey M, Goldner P, Deruzzo S, Fahrendorf T. Presented at: *2000 Spring Practice and Research Forum, American College of Clinical Pharmacy, Monterey, California, April 2-5, 2000*.

An Open Label Study Evaluating the Pharmacokinetics of ^{99m}Tc Technetium P280 (Diagnostic Agent) in Patients at Risk for Venous Thrombosis. **William B. Webster**, Tina Vo., Andrew F. Nasser, Steven J. Harwood, Sam Hakki, Robert G. Carroll, Michele Morrissey, John Camblin, Tatjana Webster; Presented at: *1999 Annual Meeting of the American College of Clinical Pharmacy, Kansas City, Missouri, October 24-27, 1999.*

Outpatient Therapy of Non-Hodgkin's Lymphoma with Iodine-131-Anti-B1 Antibody : Innovative Administration Techniques for Minimizing Radiation Exposure. **Webster WB**, Harwood SJ, Carroll, RW, Gibbons L, Schoet A, Tantranond P, Morrissey M. Presented at: *International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, October 14-16, 1999.*

Comparative Pharmacokinetics, Dosimetry, and *In-Vivo* stability of two formulations of ^{99m}Tc -Labeled Anti-granulocyte Antibody Fab' Fragment (IMMU-MN3, LeukoscanTM). Presented at: *1996 Winter Practice and Research Forum, American College of Clinical Pharmacy, Monterey, California, February 11-14, 1996.*

Cephalosporin Usage and the Emergence of Enterococcal Isolates, Evans Branch, III, Lynne C. Krop, J. Mark Trotter, and **William B. Webster**. Presented at: *Midyear Clinical Meeting, American Society of Health-System Pharmacist, Las Vegas, Nevada, December 3-7 1995.*

Plasma Pharmacokinetics of ^{99m}Tc -Immu-4 Fab' in Colorectal Cancer Patients. **Webster WB, et.al.** Presented at: *The Fifth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, October 6-8, 1994.*

Assessment of MAb Scanning for Osteomyelitis. Camblin JG, Hakki S, Harwood SJ, Morrissey MA, Patel JU, Laven DL, and **Webster WB**. Scientific Poster presented to *Fourteenth Annual Meeting of the Orthopaedic Research Society, New Orleans, La, February 21-24, 1994.*

Detection of Osteomyelitis Using ^{99m}Tc -Immu-RAIDTM-MN3 Anti-granulocyte MAb FAB' Fragments; Harwood SJ, Camblin JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, Patel JU, **Webster, WB**, and Carroll, RG. Presented at: *Southeastern Chapter, Society of Nuclear Medicine, Clearwater Beach, Florida, October 8-10, 1993.*

Use of ^{99m}Tc Technetium Anti-Granulocyte Monoclonal Antibody Fab' Fragments for the Detection of Osteomyelitis. Harwood SJ, Camblin JG, Hakki S, Morrissey MA, Laven DL, Zangara LM, Patel JU, **Webster WB** and Carroll RG. Presented to: *Tenth International Hammersmith Meeting, Paphos, Cyprus. May 3-5, 1993.*

Determining *In Vivo* ^{111}In -B72.3 Specific Binding by Pharmacokinetic Analysis of Plasma Clearance; **Webster WB**, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Presented at: *Fourth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, Sept 16-19, 1992.*

Plasma Pharmacokinetics of ^{111}In -CYT-356 Prostate Antibody; **Webster WB**, Harwood SJ, Carroll RG, Morrissey MA, Laven DL. Plasma Pharmacokinetics of ^{111}In -CYT-356 Prostate Antibody; Presented at: *Fourth Conference on Radio-immunodetection and Radioimmunotherapy of Cancer, Princeton, NJ, Sept 16-19, 1992.*

A Multidisciplinary Team Approach in Determining the Clinical Significance of an Indium-111 labeled Monoclonal Antibody for Colorectal Carcinoma. Laven DL, Morrissey MA, Zangara L, **Webster WB** and Harwood SJ: Presented at: *Pharmacy World Congress '92, FIP Section of Hospital Pharmacists, International Pharmaceutical Federation, Lyon, France, September 13-19, 1992.*

Pharmacokinetics of ^{111}In -ZCE025 MAb in Colorectal Cancer Patients: Effect of CEA on Mean-Time Parameters. **Webster WB**, Laven DL, Carroll RG, Harwood SJ and Morrissey MA: Presented at: *Pharmacy World Congress '92, FIP Section of Hospital Pharmacists, International Pharmaceutical Federation, Lyon, France, September 13-19, 1992.* (Scientific Poster Award)

Pharmacokinetics of ^{111}In -B72.3 MAb with Antibody-Antigen (TAG-72) or Antibody-Antibody (HAMA) Binding. **Webster WB**, Harwood SJ, Carroll RG, Morrissey MA and Laven DL: Presented at: *Pharmacy World Congress '92, FIP Section of Hospital Pharmacists, International Pharmaceutical Federation, Lyon, France, September 13-19, 1992.*

Pharmacokinetics of ^{111}In -ZCE025 Mab in Colorectal Cancer Patients: Effect of CEA on Mean-Time Parameters. **Webster WB**, et al. Presented at: *Seventh International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, March 4-7, 1992.*

Pharmacokinetics of ^{111}In -B72.3 MAb with Antibody-Antigen (TAG-72) or Antibody-Antigen (HAMA) Binding. **Webster WB**, Harwood SJ, Carroll RG, Morrissey MA. Presented at: *32nd Annual Meeting, Southeastern Chapter, Society of Nuclear Medicine, Hollywood, Florida. October 11-13, 1991.*

Factors Associated with the Withdrawal of Phenytoin In the Nursing Home Patient: A Practical Cost Saving Measure. Dierlam EM,

Jordan CJ, Webster T, and **Webster WB**. Presented at: *26th ASHP Midyear Clinical Meeting, New Orleans, LA. December 8-12, 1991.*

Plasma and Tissue Distribution Pharmacokinetics of ¹¹¹In Anti-CEA Murine Monoclonal Antibody in Colorectal cancer Patients. **Webster WB**, et al. Presented at: *5th World Congress of Nuclear Medicine and Biology, Montreal, Quebec, Canada. August 26-31, 1990.*

Development of Mean Transit and Residence Time Analysis of Radiolabeled Murine Monoclonal Antibody Distribution and Clearance. **Webster WB**, et al. Presented at: *The 1990 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, California. August 5-8, 1990.*

Analysis of Plasma and Tissue Distribution Pharmacokinetics for ¹¹¹IN-B72.3 Monoclonal Antibody in colorectal cancer Patients. **Webster WB**, et al. Presented at: *Fifth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, California. March 15-17, 1990.*

Comparative Analysis of Liver and Splenic Uptake in a Monoclonal Antibody Study. Wilson LA, Harwood SJ, **Webster WB**, and Morrissey MA. Presented at: *SE Chapter Meeting, Society Nuclear Medicine, Orlando, Florida, October 27-29, 1989.*

Pharmacokinetics, Biodistribution, and Dosimetry of ¹¹¹In Labeled Monoclonal Antibodies (MAb) in Colorectal Cancer Patients. **Webster WB**, Laven DL, Carroll RG, and Harwood SJ. Scientific Poster presented at: *136th American Pharmaceutical Association Annual Meeting. Anaheim, CA, April 1989.*

Usefulness of Gaussian Preprocessing, Iterative Post-Processing and Dual Isotope Organ Identification to Enhance Interpretability of ¹¹¹In MoAb SPECT Studies.

Harwood SJ, **Webster WB**, Morrissey MA, Zangara LM, Laven DL, and Carroll RG. Presented at: *Symposium on Radiolabeled Antibodies in Cancer - A Critical Review of Current Technology., Princeton, NJ, January 19, 1989.*

Biodistribution Differences of In-111 B72.3 MoAb in Nude Mice and Man. Harwood SJ, McDonald LM, Elkin MC, Laven DL, Sinni BJ, **Webster WB**, Carroll RG, Schmelter RF, Alvarez VL, and McGuire RT. Presented at: *29th Annual Meeting SE Chapter Society of Nuclear Medicine, Charleston, SC, November 4-6, 1988.*

Inflammation Related Monoclonal Antibody Localizations in Colorectal Cancer Patients. Carroll RG, Harwood SJ, Stenzel M,

Balducci L, Sinni B, Laven DL, and **Webster WB**. Presented at: *Thirty-sixth Annual Meeting, Society of Nuclear Medicine, June 1988.*

Comparison of Human Biodistribution Differences Between ^{131}I and ^{111}In Labeled B.72.3 Monoclonal Antibody.

Harwood SJ, **Webster WB**, et al. Presented at: *Second Conference on Radioimmuno-detection and Radiotherapy of Cancer, Princeton, N.J., September 8-10, 1988.*

Impact of a Pharmacy Based Phlebotomy service Integrated Into Aminoglycoside Clinical Pharmacokinetics Team. **WB Webster**, MJ Lewis, CC Morelli, L Barron, M Melville, H Chmel, Presented at: *23rd Annual ASHP Midyear Clinical Meeting, Dallas, Texas, December 4 - 8, 1988.*

Biodistribution of ^{111}In -ZCE-025 Anti-CEA Monoclonal Fab' Fragment, SJ Harwood, RG Carroll, ST DeRuzzo, **WB Webster**, D Laven, Presented at: *The Society of Nuclear Medicine 35th Annual Meeting, San Francisco, California, June 17, 1988.*

Dosimetry Implications of Tissue Distribution: Data for Fab Fragments of ZCE-025, RG Carroll, **WB Webster**, BJ Sinni, ST DeRuzzo, DL Laven, S J Harwood, Presented at: *Third International Conference on Immunoconjugates for Cancer, American Association for Cancer Research, San Diego, California, February 4 - 6, 1988.*

^{111}In -Labeled Monoclonal Antibody Plasma Pharmacokinetics in Cancer Patients, **WB Webster**, et al. Presented at: *22nd Annual ASHP Midyear Clinical Meeting, Atlanta Georgia, December 6 - 10, 1987.*

Pharmacokinetics and Tissue Distribution of ZCE-025 (Fab')₂ In Humans. SJ Harwood, **WB Webster**, et al. Presented at: *28th Annual Meeting: The Society of Nuclear Medicine, Regional Meeting, Orlando Florida, October 16 - 17, 1987.*

Stereospecific Binding of Propranolol. **WB Webster**, JA Pieper. Presented at: *American College of Clinical Pharmacy, July 8, 1985; 6th Annual Meeting, Orlando*

Signature *W. Webster, Pharm.D.*